Journal Information
Vol. 44. Issue S2.
Pages S202 (October 2022)
Share
Share
Download PDF
More article options
Vol. 44. Issue S2.
Pages S202 (October 2022)
Open Access
HOW IMPORTANT IS THROMBOCYTOSIS FOR PROGNOSIS OF MDS WITH 3Q21Q26 SYNDROME?
Visits
527
MS Coutoa,b,c, MML Meloa,b,c, DP Borgesa,b,d, VS Oliveiraa,b,d, MA Vianaa,b,d, RTG Oliveiraa,b,d, TMCE Silvaa,b, RFP Filhoa,b, SMM Magalhãesa,b,d,e, RF Pinheiroa,b,c,d,e
a Laboratório Citogenômico do Câncer (LCC), Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil
b Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil
c Programa de Pós-Graduação em Medicina Translacional, Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil
d Programa de Pós-Graduação em Ciências Médicas, Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil
e Departamento de Medicina Clínica, Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil
This item has received

Under a Creative Commons license
Article information
Special issue
This article is part of special issue:
Vol. 44. Issue S2
More info

The structural changes involving the long arm of chromosome 3 at bands 3q21 and 3q26.2 in the form of inversion are named paracentric inversion inv(3)(q21q26.2) and in myeloid neoplasms have long been recognized, but are rare. The 3q21q26 syndrome usually occurs in a high-risk myelodysplastic syndrome (MDS) or the setting of acute myeloid leukemia (AML) and is most commonly reported as inv(3)(q21q26.2). Myeloid neoplasms with inv(3) are rare disorders with an incidence of 1% in MDS and AML. Thus, this report aims to show a patient with MDS and high platelets count who presented inv(3)(q21q26.2). A 72-year-old woman looked for medical attention due to fatigue and weakness. The patient reported a history of smoking for 41 years and denied any exposure to toxic agents. At physical examination, only pale was detected. A complete blood count revealed hemoglobin 7g/dL, MCV = 94 fL, leukocytes 5,600/mm3, neutrophils 2,242/mm3 and thrombocytosis with a platelet count of 514,000/mm3. Bone marrow aspirate showed dyserythropoiesis in 30% of cells and 6,5% blasts. The bone marrow cytogenetic analysis showed 46,XX,inv(3)(q21q26.2)[16]/46,XX[4]. The diagnosis of MDS with excess blasts - 1 was established according to the 2016 World Health Organization classification and International Prognostic Scoring System was very high. While waiting for beginning treatment, the patient died of respiratory failure due to COVID-19. Myelodysplastic syndrome with inv(3)(q21q26.2) is a rare aggressive disorder that occurs in less than 1% of all MDS cases and has been associated with a poor outcome: chemoresistance, high risk of leukemic transformation and short survival. Our case showed thrombocytosis with a platelet count of 514,000/mm3. The incidence of thrombocytosis in MDS has been reported in 8% of cases with platelets > 400 ×109/L. The major report which evaluated thrombocytosis in MDS studied 2,042 cases, detecting high platelets count in 5% of cases (102/2,042). It appears that thrombocytosis does not adequately capture the aggressive nature of inv(3)(q21q26.2) in MDS but still plays an important role in the pathogenesis of this heterogeneous and dynamic disease. Our patient reported herein showed dyserythropoiesis in 30% of cells and 6,5% blasts, but nothing was detected regarding megakaryocytic lineage. Our patient died very soon after diagnosis due to viral infection. Thrombocytosis is an unusual clinical feature in MDS associated with inv(3)(q21q26.2) and the unfavorable prognosis of inv(3) is independent of thrombocytosis.

Full text is only aviable in PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Article options
Tools